Cosmo Bio USA’s oncology portfolio also provides extensive resources tailored to the study of hematologic malignancies, addressing the genetic and epigenetic regulators that control blood cell differentiation and survival. Products directed toward transcription factors, chromatin modifiers, and lineage-specific signaling proteins help researchers investigate mechanisms of leukemic transformation, clonal expansion, and immune dysregulation. Complementary reagents focus on apoptosis regulators, immune checkpoint proteins, and angiogenesis factors, allowing exploration of how malignant cells remodel their microenvironment, evade immune detection, and resist therapy.
Explore the complete portfolio of reagents for the study of liquid tumor oncology.
